liposomal glutathione raises gsh levels human studies Oral supplementation with elevates body stores of glutathione and markers of immune function Intranasal Delivery of Metabolically Resilient

Functional enrichment and network submodulation refined the focus to 43 proteins implicated in cancer pathways, namely, AKT1, APAF1, AR, BIRC7, BMP2, CASP3, CCNA2, CDK2, CDK6, CTNNA1, EGFR, ESR1, ESR2, F2, FGFR1, GSK3B, GSTA1, GSTA3, GSTM1, GSTM2, GSTP1, GSTT2B, HRAS, HSP90AA1, IGF1R, IL2, JAK2, JAK3, KIT, MAP2K1, MAPK8, MET, MMP9, NOS2, NQO1, PGF, PPARD, RARA, RARB, RXRA, RXRB, TGFBR1 and XIAP

Biopolymer-Liposome hybrid systems for controlled delivery of bioactive compounds: recent advances

Pharmaceutical companies have invested hundreds of millions of dollars in developing disease-modifying drugs, including monoclonal antibodies, inhibitors (e.g., aducanumab, donanemab, donepezil, memantine), while neurologists, psychiatrists, foundations, families, and affected individuals continue to await a transformative therapeutic breakthrough (Knopman et al., 2021)

[1] Liposomal technology directly addresses the absorption barrier